緩釋輔料市場－2026-2031年預測

緩釋輔料市場預計將從 2025 年的 16.39 億美元成長到 2031 年的 25.36 億美元，維持 7.55% 的複合年成長率。

緩釋輔料市場是整個醫藥輔料產業中一個特殊且重要的細分市場，專注於控制和維持藥物從製劑中釋放的功能性成分。這些輔料旨在改變活性藥物成分（API）的溶解、擴散或侵蝕，從而延長療效、減少給藥頻率並提高患者依從性。這些功能性材料主要用於片劑和膠囊等口服固態製劑，在開發滿足不斷變化的臨床和以患者為中心的先進藥物遞送系統中發揮著至關重要的作用。

市場成長的關鍵促進因素之一是患者對更容易服用的劑型的需求不斷成長，尤其是在老年人和兒童等特定人群中。對於這些族群而言，簡化給藥方案（例如每日一次或減少給藥頻率）對於提高用藥依從性和治療效果至關重要。緩釋製劑正是為了滿足這一需求，這極大地激勵了藥物研發人員將特殊的控制釋放輔料應用於新型和生命週期管理的產品。這種人口趨勢也支撐了對創新輔料解決方案的持續需求。

市場成長也受到藥用聚合物應用範圍不斷擴大和持續進步的推動，而藥用聚合物正是緩釋機制的核心技術。羥丙甲纖維素（HPMC）、乙基纖維素、聚乙酸乙烯酯和各種聚甲基丙烯酸酯等聚合物經過精心設計，能夠精確控制藥物釋放動力學。從簡單的粘合劑發展到能夠實現標靶釋放曲線（例如，pH依賴性、時間控制）的先進多功能輔料，是推動創新的主要動力。這些聚合物的性能、穩定性以及監管合規性對於製劑研發人員開發複雜的學名藥和新型緩釋製劑至關重要。

口服給藥作為首選給藥途徑的主導地位對市場產生了重大影響。口服劑型在病患接受度、生產擴充性和成本效益方面具有無可比擬的優勢。在此領域，緩釋片和膠囊的研發是提高藥物性能的重要方向。與新型給藥途徑相比，監管機構對口服緩釋技術的相對認可加快了其研發和核准進程，鼓勵製藥公司利用緩釋輔料來提升產品價值和差異化優勢。

宏觀層面的一個重要促進因素是全球抗菌藥物抗藥性（AMR）的挑戰。不合理使用速效抗生素，尤其是由於複雜的給藥方案導致患者依從性差，被認為是抗藥性出現的重要因素。緩釋製劑能夠以更少的劑量維持更長時間的有效藥物濃度，有助於完成整個療程並提高患者依從性，進而降低抗藥性的風險。這項公共衛生迫切需求促使人們探索抗感染藥物的緩釋策略，並為相關輔料技術開闢了一條獨特的成長路徑。

市場也受益於製藥公司利用藥物遞送技術（包括藥物輸送）來實現產品差異化並延長其商業生命週期的更廣泛趨勢，尤其是在專利到期的情況下。將現有活性藥物成分 (API) 重新配製成緩釋劑型，透過提供臨床益處、提高市場競爭力以及提供生命週期管理途徑，推動了對支持此類創新的輔料的需求。

從區域來看，北美仍然是一個關鍵且成熟的市場。其主導地位得益於眾多擁有強大研發能力的跨國製藥公司、積極開發複雜學名藥（包括緩釋產品）的蓬勃發展的學名藥產業，以及美國食品藥物管理局(FDA) 清晰的法規結構。該地區對先進藥物遞送技術和以患者為中心的劑型的關注，持續推動對高性能輔料的高需求。

同時，亞太地區被定位為高成長且潛力巨大的市場。這主要得益於該地區藥品生產能力的快速擴張、醫療基礎設施投資的不斷增加、需要長期用藥的慢性病患者人數的上升，以及全球供應商為滿足不斷成長的市場需求而日益本地化的輔料生產。隨著醫藥標準和創新技術的不斷發展，該地區蘊藏著巨大的成長機會。

在競爭激烈的市場環境中，主要的特種化學品和輔料生產商憑藉產品系列的廣度、技術專長、產品穩定性、法規支援以及向配方師提供可靠科學數據的能力展開競爭。為了拓展商業性影響力，企業透過併購和合作等策略活動屢見不鮮。

總之，緩釋輔料市場是現代以病人為中心的藥物研發不可或缺的一部分。其成長動力源自於提高用藥依從性的持續需求、聚合物科學的進步、藥物傳遞策略在提升治療價值的應用。未來發展將受到以下因素的影響：能夠響應生理觸發的多功能智慧輔料的創新、對複雜學名藥日益成長的需求，以及對用於支持難溶性藥物等原料藥性藥物緩釋製劑的輔料的需求。在該市場取得成功需要對製劑科學有深刻的理解，與藥物研發人員密切合作，並致力於功能性材料設計的品質和創新。

本報告的主要優勢：

• 深入分析：提供對主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、行業垂直領域和其他細分市場。
• 競爭格局：了解全球主要參與者的策略舉措，並了解透過正確的策略進入市場的機會。
• 市場促進因素與未來趨勢：探討影響市場的動態因素和關鍵趨勢及其對未來市場發展的影響。
• 可操作的建議：利用這些見解，在快速變化的環境中製定策略決策，發展新的商業機會和收入來源。
• 受眾廣泛：對Start-Ups、研究機構、顧問公司、中小企業和大型企業都很有用且經濟實惠。

您打算如何使用這份報告？

產業與市場分析、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法規結構及影響、新產品開發、競爭情報

報告範圍：

• 2021年至2025年的歷史數據和2026年至2031年的預測數據
• 成長機會、挑戰、供應鏈前景、法規結構與趨勢分析
• 競爭定位、策略和市場佔有率分析
• 按業務板塊和地區（包括國家）分類的收入和預測評估
• 公司概況（策略、產品、財務資訊、關鍵發展等）

目錄

第1章執行摘要

第2章 市場概覽

• 市場概覽
• 市場定義
• 調查範圍
• 市場區隔

第3章 商業情境

• 市場促進因素
• 市場限制
• 市場機遇
• 波特五力分析
• 產業價值鏈分析
• 政策與法規
• 策略建議

第4章 技術展望

第5章 緩釋輔料市場（依類型分類）

• 介紹
• 聚合物
• 脂質
• 微球

6. 依產品類型分類的緩釋輔料市場

• 介紹
• 片劑和膠囊
• 修補
• 植入
• 其他

7. 依給藥途徑分類的緩釋輔料市場

• 介紹
• 口服
• 注射
• 經皮吸收劑
• 其他

8. 按地區分類的控釋輔料市場

• 介紹
• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他
• 歐洲
  • 德國
  • 法國
  • 英國
  • 西班牙
  • 其他
• 中東和非洲
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 印尼
  • 泰國
  • 其他

第9章 競爭格局與分析

• 主要企業和策略分析
• 市佔率分析
• 合併、收購、協議和合作
• 競爭對手儀錶板

第10章：公司簡介

• BASF SE
• International Flavors & Fragrances, Inc.
• Ashland
• Evonik Industries
• Croda International Plc
• Gattefosse
• Merck KGaA
• MEGGLE GmbH & Co. KG
• Roquette Freres
• CD Formulation

第11章附錄

• 貨幣
• 先決條件
• 基準年和預測年時間表
• 相關人員的主要收益
• 調查方法
• 簡稱

Sustained Release Excipients Market, sustaining a 7.55% CAGR, is anticipated to reach USD 2.536 billion in 2031 from USD 1.639 billion in 2025.

The sustained release excipients market is a specialized and critical segment within the broader pharmaceutical excipients industry, focused on the functional ingredients that enable controlled and prolonged drug release from a dosage form. These excipients are engineered to modulate the dissolution, diffusion, or erosion of the active pharmaceutical ingredient (API), thereby extending its therapeutic effect, reducing dosing frequency, and improving patient compliance. Primarily utilized in oral solid dosage forms like tablets and capsules, these functional materials are fundamental to developing advanced drug delivery systems that meet evolving clinical and patient-centric needs.

A primary driver of market growth is the increasing demand for patient-friendly dosage forms tailored to specific populations, particularly the elderly and pediatric patients. For these groups, simplified dosing regimens-achieved through once-daily or less-frequent administration-are crucial for improving adherence and therapeutic outcomes. Sustained release formulations address this need directly, creating a strong incentive for pharmaceutical developers to incorporate specialized release-modifying excipients into new and lifecycle-managed products. This demographic trend underpins a sustained demand for innovative excipient solutions.

The market is further propelled by the expanding use and continuous advancement of pharmaceutical polymers, which constitute the core technology for most sustained release mechanisms. Polymers such as hypromellose (HPMC), ethyl cellulose, polyvinyl acetate, and various polymethacrylates are engineered to provide precise control over drug release kinetics. Their evolution from simple binding agents to sophisticated, multifunctional excipients capable of enabling targeted release profiles (e.g., pH-dependent, time-controlled) is a key innovation driver. The performance, consistency, and regulatory acceptance of these polymers make them indispensable for formulators developing complex generic and novel sustained release products.

The dominance of oral drug delivery as the preferred administration route significantly influences the market. Oral dosage forms offer unparalleled advantages in terms of patient acceptance, manufacturing scalability, and cost-effectiveness. Within this segment, the development of sustained release tablets and capsules represents a major focus area for improving drug performance. The relative regulatory familiarity with oral modified-release technologies, compared to more novel delivery routes, facilitates development and approval, encouraging pharmaceutical companies to leverage sustained release excipients to enhance product value and differentiation.

A notable macro-level driver is the global challenge of antimicrobial resistance (AMR). Inappropriate use of immediate-release antibiotics, often due to complex dosing schedules leading to patient non-adherence, is a recognized contributor to resistance. Sustained release formulations that maintain effective drug concentrations over longer periods with fewer doses can support more complete treatment courses and improved adherence, potentially mitigating one factor in resistance development. This public health imperative encourages exploration of controlled-release strategies for anti-infectives, creating a specific, though niche, growth avenue for relevant excipient technologies.

The market also benefits from the broader trend of pharmaceutical companies utilizing drug delivery technologies, including sustained release, to differentiate products and extend commercial lifecycles, especially in the face of patent expirations. Reformulating an existing API into a controlled-release version can offer clinical benefits, improve market competitiveness, and provide a pathway for lifecycle management, thereby driving demand for the excipients that enable such innovations.

Geographically, North America remains a mature and dominant market. This leadership is supported by a concentration of multinational pharmaceutical companies with extensive R&D capabilities, a robust generic drug industry active in developing complex generics (including modified-release products), and a well-defined regulatory framework from the U.S. Food and Drug Administration (FDA). The region's focus on advanced drug delivery and patient-centric dosage forms sustains high demand for high-performance excipients.

Concurrently, the Asia-Pacific region is identified as a high-growth market with significant potential. This is driven by the rapid expansion of regional pharmaceutical manufacturing capabilities, increasing investment in healthcare infrastructure, a growing burden of chronic diseases requiring long-term medication, and the rising localization of excipient production by global suppliers to serve this expanding market. The region presents a substantial opportunity for growth as pharmaceutical standards and innovation continue to advance.

The competitive landscape features major specialty chemical and excipient manufacturers that compete on the basis of product portfolio breadth, technical expertise, consistency, regulatory support, and the ability to provide robust scientific data to formulators. Strategic activities, including mergers, acquisitions, and partnerships, are common as companies seek to expand their technology platforms, gain access to novel polymer chemistries, and strengthen their global commercial footprint.

In conclusion, the sustained release excipients market is integral to the development of modern, patient-centered pharmaceuticals. Its growth is underpinned by enduring needs for improved medication adherence, the sophistication of polymer science, and the strategic use of drug delivery to enhance therapeutic value. Future development will be shaped by innovations in multifunctional and "smart" excipients that respond to physiological triggers, the increasing demand for complex generic products, and the need for excipients that support the development of sustained release formulations for challenging APIs, including poorly soluble drugs. Success in this market requires a deep understanding of formulation science, close collaboration with pharmaceutical developers, and a commitment to quality and innovation in functional material design.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Sustained Released Excipients Market Segmentation

• By Type
• Polymers
• Lipids
• Micrspheres
• By Product Type
• Tablets & Capsules
• Patches
• Implants
• Others
• By Route of Administration
• Oral
• Injectables
• Transdermal
• Others
• By Geography
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. SUSTAINED RELEASED EXCIPIENTS MARKET BY TYPE

• 5.1. Introduction
• 5.2. Polymers
• 5.3. Lipids
• 5.4. Micrspheres

6. SUSTAINED RELEASED EXCIPIENTS MARKET BY PRODUCT TYPE

• 6.1. Introduction
• 6.2. Tablets & Capsules
• 6.3. Patches
• 6.4. Implants
• 6.5. Others

7. SUSTAINED RELEASED EXCIPIENTS MARKET BY ROUTE OF ADMINISTRATION

• 7.1. Introduction
• 7.2. Oral
• 7.3. Injectables
• 7.4. Transdermal
• 7.5. Others

8. SUSTAINED RELEASED EXCIPIENTS MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. BASF SE
• 10.2. International Flavors & Fragrances, Inc.
• 10.3. Ashland
• 10.4. Evonik Industries
• 10.5. Croda International Plc
• 10.6. Gattefosse
• 10.7. Merck KGaA
• 10.8. MEGGLE GmbH & Co. KG
• 10.9. Roquette Freres
• 10.10. CD Formulation

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations